Investors in Delcath Systems (NASDAQ:DCTH) have seen splendid returns of 221% over the past three years [Yahoo! Finance]
Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program [Yahoo! Finance]